Oncotarget Offers Insight on New Cancer Therapies and Treatment


For decades now, cancer has been the leading medical problem. The most unnerving fact about the disease is its ability to replicate in the body’s immunity without being detected in the earlier stages. Because of the challenges cancer poses to humanity, scientists and researchers have invested in medical research to curb the disease. Scientific research presently provides best solutions for fighting diseases like cancer. Through science, physicians can access various data and therapies for cancer treatment. Follow Mikhail on Google Scholar


Science continues to contribute to the research and dissemination of information related to the diagnosis and treatment of cancer. Through the same research, Oncotarget was established. It is a medical peer review journal published on a weekly basis with the aim of educating the society on treatment and therapies for cancer. The core mission of Oncotarget objective is sharing and providing information on cancer and other life-threatening diseases across the world.

Know more: https://www.crunchbase.com/person/mikhail-blagosklonny


With the global drive focused on creating a disease-free society, many institutions and researchers have been adopting Oncotarget as a strategy towards this cause. Being a scientific journal, Oncotarget has made valuable gains marked by the health articles published in it. Recently, the Journal featured an article on the health hazards of smoking e-cigarettes. Unlike the common belief that these cigarettes are healthy, the article highlighted its risk factors. E-cigarettes have adverse negative effects to the gums.

Cervical Cancer

Additionally, Oncotarget published research on a new type of cervical cancer. It highlighted the side effects of cancer drugs as causing weight loss. The new findings are essential tools in battling cancer as well as providing an innovative platform for the e-cigarette research. The results also indicate that scientific research can disseminate information on common misconceptions related to common knowledge.


Being an open source scientific journal, Oncotarget plays a vital role in disseminating information to researchers, scientists, community, and donors. Through its weekly publications, Oncotarget can reach many people in the society. It, therefore, means that the journal, under the leadership of prominent scientists like Mikhail Blagosklonny, has widened its scope of publication from oncology to various fields like pharmacology and aging. Visit classroomvoices.org to read more about Mikhail.

Clay Siegall Is Proud of His Company

As the Founder, President, Chief Executive Officer, and Chairman of Seattle Genetics, Inc. headquartered in Bothell, Washington, Clay Siegall is happy to have tackled his very big decision to form an innovative clinical-stage biotechnology company to develop monoclonal antibody-based therapies to advance the treatment of cancer and autoimmune diseases for blood-related cancers and solid tumors.

The company’s therapies are designed to meet unmet medical needs and improve important treatment outcomes for the affected patients. Its industry-leading antibody-drug conjugate (ADC) harnesses the antibodies’ ability as cell-killing agents to be delivered to infected cancer cells.

ADCETRIS® (brentuximab vedotin), which is the lead product collaborating with Takeda Pharmaceutical Company Limited, comprises the first in the class of ADCs that are commercially available in 65 countries to treat Hodgkin lymphoma (HL) as well as relapsed systemic anaplastic large cell lymphoma (sALCL). There are a number of products, clinical trials, and research projects that are being undertaken.

Clay Siegall, Ph.D., in 1998 co-founded Seattle Genetics and guided the capital-raising activities that secured over $675 million through private and public financing for the company’s initial public offering in 2001. His leadership has headed a diverse pipeline of antibody-based cancer therapies. That included ADCETRIS (brentuximab vedotin) which, in 2011, was granted approval by the U.S. Food and Drug Administration (FDA).

On Tuesday, November 8, 2016, Siegall presented at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, Arizona. The presentation was webcast live and is available for replay from the website at www.seattlegenetics.com.

Before Seattle Genetics, Dr. Siegall was very active from 1991 to 1997 with the Bristol-Myers Squibb Pharmaceutical Research Institute. Prior to that, from 1988 to 1991, he was with the National Cancer Institute, National Institutes of Health. He currently also serves on the Board of Directors of the private biotechnology company Alder BioPharmaceuticals, gives frequent professional talks, is an author of over 70 publications, and is the holder of 15 patents.

Clay Seagall’s Skills and Experience to be Incorporated in Mirna Therapeutics

Recently Clay Siegall, the co-founder, Chief Executive Office, President and Chairman of Board of Directors at Seattle Genetics, was appointed as an outside director to the Board of Mirna Therapeutics. The therapeutic company, which specializes in the commercialization of microRNA therapeutics, executed this appointment due to Dr. Clay Siegall’s experience in the pharmaceutical industry and his impressive achievement in establishing a successful oncology company. Dr. Paul Lammers, the president and Chief Executive Officer of Mirna Therapeutics, believes that Dr. Siegall’s appointment will be beneficial to his company in aiding the advancement of microRNA-based Therapeutics.
The therapeutic company has been for a while involved in the miRNA field, which is a crucial aspect in the research of cancer. Dr. Siegall states that he is more than prepared to join the team at Mirna, which has a strong pipeline of product candidates, which shares his long time ambition to help millions of patients the world over who are in desperate need. Theses miRNAs, which are 20-25 nucleotides long, interact with messenger RNAs thereby affecting the gene expression. Over 1400 miRNAs are encoded in the human genome and unlike siRNAs which are not. The miRNAs compose of an estimate of 2% of all mammalian genes.
Dr. Siegall co-founded Seattle Genetics in 1998, which has over the years maintained as a leader in various antibody-based therapies, under his impressive leadership and monitoring. These treatments are enhanced to meet the medical needs of cancer patients from all over the world. The first commercial product released by Dr. Siegall’s company was ADCETRIS, which gained immense recognition with the public and was approved in August 2011. Besides, the company has also initiated a couple of strategic collaborations with major biotechnology and pharmaceutical companies in oncology.
His impressive educational background can be traced to the University of Maryland, where he pursued Bachelors in Zoology. Dr. Siegall then went further on his studies to attain a Ph.D. in Genetics from George Washington University. Aside from his corporate achievement with Seattle Genetics, he has also served in Alder Biopharmaceutical as part of the Board of Directors, the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. In addition to holding 15 patents, Dr. Siegall is also an author of over 70 publications.